€1.2m · Other round · AI · Gothenburg, Sweden
Gothenburg-based Aventix has raised €1.2m in financing led by Kost Capital and Voima Ventures to bring its first laboratory instrument, Scarlett 01, to more customers in Europe and North America. Aventix describes the round as pre-seed; Tech.eu classifies the event as Other, which determines the funding tag used here. The company says the capital will support its Early Access Program, expand its applications and software teams, and fund additional analytical capabilities on the underlying sensor platform.
Scarlett 01 tackles a deceptively basic source of experimental error: whether a liquid-handling system has dispensed the intended volume into every well of a microplate. Small deviations change concentrations and can undermine assay reproducibility, yet may only become visible after an experiment fails. Aventix says the instrument measures an entire 96-well plate in as little as 30 seconds without touching the samples.
The system uses Aventix Chromatic Core Technology, an optical method that turns chromatic aberration into a distance measurement. Its SensVue software then converts the measured liquid-surface geometry into a volume while accounting for the meniscus and plate geometry. Aventix points to an independent VTT MIKES validation study using DMSO in a 384-well plate, with the reference syringe calibrated by RISE under ISO 8655 methods.
Reliable inputs are the product, not a side effect
Aventix is positioning Scarlett as measurement infrastructure for laboratories adopting automation and AI. Models can help analyse experimental data, but they cannot repair an unnoticed dispensing error upstream. Capturing a fast, non-contact volume check at the point of work could therefore reduce failed experiments while creating more trustworthy data for later analysis.
The commercial mechanism depends on fitting that check into existing workflows. A benchtop system can be easier to adopt than replacing liquid-handling equipment, while software can turn each measurement into a traceable quality-control record. The test for Aventix is whether laboratories see enough savings in avoided reruns, investigation time and data uncertainty to make volume verification a routine step rather than an occasional diagnostic.
The company is already building distribution around that premise. Its Early Access Program covers pharmaceutical, chemical, agricultural and cosmetic R&D, and Aventix has announced partners for Spain and Portugal and for the Benelux region. Scarlett 01 remains in limited early access, so repeat deployments and customer evidence will matter more than the breadth of potential applications.
Aventix was founded by Erik Gatenholm and Hector Martinez, who previously co-founded CELLINK, later BICO Group. Their earlier experience scaling life-science tools gives the company relevant operating history, but Scarlett still has to prove that its first measurement application can anchor a broader sensor-and-software platform.
Sources checked:
Aventix company announcement · Voima Ventures announcement · Breakit reporting · Tech.eu Funding Explorer
